Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-01-13

Clinical Trial Update: Imatinib Mesylate in Treating Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating imatinib mesylate in patients with primary myelofibrosis. The study was terminated and results were posted in January 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Imatinib mesylate (Imatinib)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Chronic Myeloproliferative Disorders | Phase 2 | Status: TERMINATED | Results posted: 2012-01-13